Clinical Report: Integrating Autoantibodies and Inflammatory Markers to Forecast Bone Metastasis Risk in Patients with Non-Small Cell Lung Cancer
Overview
This study developed and validated a nomogram model that integrates autoantibodies and systemic inflammation markers to predict bone metastasis risk in non-small cell lung cancer (NSCLC) patients. The model demonstrated strong discriminatory ability and improved predictive performance with the inclusion of novel biomarkers.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with a significant proportion of patients developing bone metastases, which adversely affect quality of life. Current diagnostic methods primarily rely on imaging, often identifying metastases at advanced disease stages. There is a pressing need for validated predictive models to facilitate early intervention and improve patient outcomes.
Data Highlights
Variable
AUC (Training Cohort)
AUC (Validation Cohort)
Nomogram
0.921 (95% CI: 0.887-0.955)
0.870 (95% CI: 0.795-0.945)
Continuous NRI
0.822 (P< 0.001)
IDI
0.121 (P<0.001)
Key Findings
The nomogram included seven key variables: histology, TNM stage, anti-ENAs, SIRI, LWR, anti-AMA-M2, and ANA fluorescence pattern.
Receiver operating characteristic curve (AUC) for the training cohort was 0.921.
Receiver operating characteristic curve (AUC) for the validation cohort was 0.870.
Calibration plots indicated good agreement between predicted and observed outcomes.
Decision Curve Analysis (DCA) showed higher net benefit for the nomogram compared to standard treatment strategies.
The inclusion of novel biomarkers significantly enhanced the model's predictive performance.
Clinical Implications
The developed nomogram provides a reliable tool for predicting bone metastasis risk in NSCLC patients, which may assist in clinical decision-making. Incorporating autoantibody and inflammation-related biomarkers can improve risk stratification and facilitate timely interventions.
Conclusion
The nomogram represents a significant advancement in predicting bone metastasis risk in NSCLC patients, integrating novel biomarkers to enhance predictive accuracy. This tool may support clinicians in making informed decisions regarding patient management.
